Cargando…
Identification of novel bacterial DNA gyrase inhibitors: An in silico study
Owing to essential role in bacterial survival, DNA gyrase has been exploited as a validated drug target. However, rapidly emerging resistance to gyrase-targeted drugs such as widely utilized fluoroquinolones reveals the necessity to develop novel compounds with new mechanism of actions against this...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962306/ https://www.ncbi.nlm.nih.gov/pubmed/27499795 |
_version_ | 1782444810003546112 |
---|---|
author | Rahimi, Hamzeh Najafi, Ali Eslami, Habib Negahdari, Babak Moghaddam, Mehrdad Moosazadeh |
author_facet | Rahimi, Hamzeh Najafi, Ali Eslami, Habib Negahdari, Babak Moghaddam, Mehrdad Moosazadeh |
author_sort | Rahimi, Hamzeh |
collection | PubMed |
description | Owing to essential role in bacterial survival, DNA gyrase has been exploited as a validated drug target. However, rapidly emerging resistance to gyrase-targeted drugs such as widely utilized fluoroquinolones reveals the necessity to develop novel compounds with new mechanism of actions against this enzyme. Here, an attempt has been made to identify new drug-like molecules for Shigella flexneri DNA gyrase inhibition through in silico approaches. The structural similarity search was carried out using the natural product simocyclinone D8, a unique gyrase inhibitor, to virtually screen ZINC database. A total of 11830 retrieved hits were further screened for selection of high-affinity compounds by implementing molecular docking followed by investigation of druggability according to Lipinski’s rule, biological activity and physiochemical properties. Among the hits initially identified, three molecules were then confirmed to have reasonable gyrase-binding affinity and to follow Lipinski’s rule. Based on these in silico findings, three compounds with different chemical structures from previously identified gyrase inhibitors were proposed as potential candidates for the treatment of fluoroquinolone-resistant strains and deserve further investigations. |
format | Online Article Text |
id | pubmed-4962306 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-49623062016-08-05 Identification of novel bacterial DNA gyrase inhibitors: An in silico study Rahimi, Hamzeh Najafi, Ali Eslami, Habib Negahdari, Babak Moghaddam, Mehrdad Moosazadeh Res Pharm Sci Original Article Owing to essential role in bacterial survival, DNA gyrase has been exploited as a validated drug target. However, rapidly emerging resistance to gyrase-targeted drugs such as widely utilized fluoroquinolones reveals the necessity to develop novel compounds with new mechanism of actions against this enzyme. Here, an attempt has been made to identify new drug-like molecules for Shigella flexneri DNA gyrase inhibition through in silico approaches. The structural similarity search was carried out using the natural product simocyclinone D8, a unique gyrase inhibitor, to virtually screen ZINC database. A total of 11830 retrieved hits were further screened for selection of high-affinity compounds by implementing molecular docking followed by investigation of druggability according to Lipinski’s rule, biological activity and physiochemical properties. Among the hits initially identified, three molecules were then confirmed to have reasonable gyrase-binding affinity and to follow Lipinski’s rule. Based on these in silico findings, three compounds with different chemical structures from previously identified gyrase inhibitors were proposed as potential candidates for the treatment of fluoroquinolone-resistant strains and deserve further investigations. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4962306/ /pubmed/27499795 Text en Copyright: © Research in Pharmaceutical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Rahimi, Hamzeh Najafi, Ali Eslami, Habib Negahdari, Babak Moghaddam, Mehrdad Moosazadeh Identification of novel bacterial DNA gyrase inhibitors: An in silico study |
title | Identification of novel bacterial DNA gyrase inhibitors: An in silico study |
title_full | Identification of novel bacterial DNA gyrase inhibitors: An in silico study |
title_fullStr | Identification of novel bacterial DNA gyrase inhibitors: An in silico study |
title_full_unstemmed | Identification of novel bacterial DNA gyrase inhibitors: An in silico study |
title_short | Identification of novel bacterial DNA gyrase inhibitors: An in silico study |
title_sort | identification of novel bacterial dna gyrase inhibitors: an in silico study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962306/ https://www.ncbi.nlm.nih.gov/pubmed/27499795 |
work_keys_str_mv | AT rahimihamzeh identificationofnovelbacterialdnagyraseinhibitorsaninsilicostudy AT najafiali identificationofnovelbacterialdnagyraseinhibitorsaninsilicostudy AT eslamihabib identificationofnovelbacterialdnagyraseinhibitorsaninsilicostudy AT negahdaribabak identificationofnovelbacterialdnagyraseinhibitorsaninsilicostudy AT moghaddammehrdadmoosazadeh identificationofnovelbacterialdnagyraseinhibitorsaninsilicostudy |